by The targeted cancer therapies market is estimated to witness high growth owing to advancements in precision medicine. Targeted cancer therapies work by targeting specific genes or proteins that are essential for cancer cell growth and survival, thereby reducing damage to normal cells. These therapies are designed to interfere with specific molecular targets that are involved in the growth, progression, and spread of cancer. Some of the major targeted therapies include monoclonal antibodies, small molecule inhibitors, and immunotherapies. Targeted therapies hold promising potential due to their ability to precisely attack cancer cells with minimal damage to healthy cells.
The global targeted cancer therapies market is estimated to be valued at US$ 1847.47 Bn in 2024 and is expected to exhibit a CAGR of 15% over the forecast period of 2024 to 2030.
Advancements in precision medicine and drug development have enabled identification of specific molecular targets in various cancers, driving the demand for targeted therapies.
Key Takeaways
Key players operating in the targeted cancer therapies market are Wacker Chemie, Evonik Industries, Cabot Corporation, Solvay SA, PPG Industries, Madhu Silica, Fuji Silysia Chemical, Tosoh Silica Corporation, Oriental Silicas Corporation etc.
The key opportunities in the targeted cancer therapies market include development of combination therapies, development of novel targeted agents against various cancers, approvals for new targeted drugs and identification of new molecular targets.
Technological advancements such as development of bioinformatics tools for comprehensive molecular profiling of tumors, advances in imaging techniques for precision diagnosis and advancements in drug delivery systems are estimated to boost the targeted cancer therapies market.
Market drivers
One of the major drivers for the Targeted Cancer Therapies Market Share is increasing adoption of personalized medicine. Advancements in precision diagnostics have enabled comprehensive molecular characterization of tumors, identification of novel biomarkers and detection of genetic mutations driving cancer development. This has led to development of targeted therapies against specific biomarkers and mutations in cancer cells. Additionally, targeted therapies have fewer side effects compared to conventional chemotherapy drugs thereby improving patient quality of life and compliance to treatment regimens.
Current challenges in the Targeted Cancer Therapies Market
The targeted cancer therapies market is facing various challenges currently including rising drug development costs, complexities associated with targeted therapies, need for specialized diagnostic tests, complexity of pathways driving cancers, side effects of targeted therapies etc. The drug development process is highly complex and expensive which makes it difficult for small players to develop new targeted drugs. The molecular pathways driving different cancer types are also not fully understood which poses challenges in developing therapies targeting specific pathways and mutations. Many targeted therapies also have severe side effects when used which redues patient compliance. Further, specialized molecular diagnostic tests are required along with therapies to identify patients suitable for specific targeted treatments which increases costs.
SWOT Analysis
Strength: Targeted therapies have higher efficacy and less side effects compared to conventional chemotherapy. They target specific mutations driving cancer growth.
Weakness: High development costs of targeted drugs. Complex molecular pathways of cancers pose challenges.
Opportunity: Continued research on cancer pathways will help identify new drug targets. Growth in compananion diagnostics market.
Threats: Safety concerns over side effects of some therapies. Intense competition among players.
Geographical regions concentrated in terms of value
North America accounts for the largest share in the global targeted cancer therapies market currently in terms of value. This is owing to factors such as advanced healthcare infrastructure, growing cancer incidence, presence of key players, high adoption of new targeted drugs etc. Europe is the second largest market focused majorly on lung and breast cancer therapies.
Fastest growing region
The Asia Pacific region is expected to register the fastest growth during the forecast period in the targeted cancer therapies market. This is due to improving healthcare infrastructure, rising disposable incomes, increasing government initiatives to promote cancer diagnosis and treatment etc across major Asian countries. The growing cancer burden in developing economies will also boost demand for better treatment options like targeted therapies.
*Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it
